Management of the neurological manifestations of APS - what do the trials tell us?

被引：20

作者：

Brey, RL ^{[1
]}

机构：

[1] Univ Texas, Ctr Hlth Sci, Div Med Neurol, San Antonio, TX 78229 USA

来源：

THROMBOSIS RESEARCH | 2004年 / 114卷 / 5-6期

关键词：

antiphospholipid syndrome; antiphospholipid antibodies; cerebrovascular disease;

D O I：

10.1016/j.thromres.2004.06.018

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose: To systematically review evidence from clinical trials about the management of neurological manifestations of Antiphospholipid Syndrome (APS). Methods: Articles reporting case-control, cohort and prospective studies and treatment trials of primary or secondary stroke prevention in patients with aPL were identified in an OVID literature search from 1966 to 2004, using the keywords: APS, aPL and cerebrovascular disease. Articles were evaluated according to the standard system for assessing medical evidence to answer the following questions: (1) What is the role of aPL and recurrent stroke risk in both primary and secondary APS populations? (2) What is the evidence to support specific treatment strategies for secondary prevention of aPL-associated stroke? (3) What is the evidence to support specific treatment strategies for primary prevention of aPL-associated stroke? Conclusions: (1) aPL are a risk factor for incident stroke (Grade A, established as useful for the given condition in the specified population). (2) The evidence to support the rote of aPL in recurrent stroke is conflicting and, therefore, inconclusive. (3) Warfarin at moderate-intensity doses is equally effective in preventing a recurrent thrombotic event as warfarin at high-intensity doses in patients with APS (Grade A evidence, established as useful for the given condition in the specified population). (4) Warfarin, at moderate-intensity doses is as effective as aspirin (at a dose of 325 mg/ day) in preventing recurrent thrombotic events in patients who are aPL-positive at the time of an initial stroke (Grade B evidence, probably useful for the given condition in the given population). (5) Currently there are no data to support the use of any prophylactic therapy in patients with aPL and no clinical manifestations for the purposes of preventing an incident stroke. (c) 2004 Elsevier Ltd. All rights reserved.

引用

页码：489 / 499

页数：11

共 44 条

[1] Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome [J].

Adams, MJ ;

Donohoe, S ;

Mackie, IJ ;

Machin, SJ .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (02) :375-379

[2] Anticardiolipin antibodies are not an independent risk factor for stroke - An incident case-referent study nested within the MONICA and Vasterbotten Cohort Project [J].

Ahmed, E ;

Stegmayr, B ;

Trifunovic, J ;

Weinehall, L ;

Hallmans, G ;

Lefvert, AK .

STROKE, 2000, 31 (06) :1289-1293

[3] Antiphospholipid antibodies in the acute phase of cerebral ischaemia in young adults: A descriptive study of 139 patients [J].

Blohorn, A ;

Guegan-Massardier, E ;

Triquenot, A ;

Onnient, Y ;

Tron, F ;

Borg, JY ;

Mihout, B .

CEREBROVASCULAR DISEASES, 2002, 13 (03) :156-162

[4] Antiphospholipid antibodies and stroke in young women [J].

Brey, RL ;

Stallworth, CL ;

McGlasson, DL ;

Wozniak, MA ;

Wityk, RJ ;

Stern, BJ ;

Sloan, MA ;

Sherwin, R ;

Price, TR ;

Macko, RF ;

Johnson, CJ ;

Earley, CJ ;

Buchholz, DW ;

Hebel, JR ;

Kittner, SJ .

STROKE, 2002, 33 (10) :2396-2400

[5] ANTIPHOSPHOLIPID ANTIBODIES AND CEREBRAL-ISCHEMIA IN YOUNG-PEOPLE [J].

BREY, RL ;

HART, RG ;

SHERMAN, DG ;

TEGELER, CH .

NEUROLOGY, 1990, 40 (08) :1190-1196

[6] β2-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction -: The Honolulu Heart Program [J].

Brey, RL ;

Abbott, RD ;

Curb, JD ;

Sharp, DS ;

Ross, GW ;

Stallworth, CL ;

Kittner, SJ .

STROKE, 2001, 32 (08) :1701-1706

[7] Antiphospholipid syndrome -: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients [J].

Cervera, R ;

Piette, JC ;

Font, J ;

Khamashta, MA ;

Cervera, R ;

Piette, JC ;

Font, J ;

Khamashta, MA ;

Shoenfeld, Y ;

Camps, MT ;

Jacobsen, S ;

Lakos, G ;

Tincani, A ;

Kontopoulou-Griva, I ;

Galeazzi, M ;

Meroni, PL ;

Derksen, RHWM ;

de Groot, PG ;

Gromnica-Ihle, E ;

Baleva, M ;

Mosca, M ;

Bombardieri, S ;

Houssiau, F ;

Gris, JC ;

Quéré, I ;

Hachulla, E ;

Vasconcelos, C ;

Roch, B ;

Fernández-Nebro, A ;

Boffa, MC ;

Hughes, GRV ;

Ingelmo, M .

ARTHRITIS AND RHEUMATISM, 2002, 46 (04) :1019-1027

[8] Morbidity and mortality in systemic lupus erythematosus during a 10-year period -: A comparison of early and late manifestations in a cohort of 1,000 patients [J].

Cervera, R ;

Khamashta, MA ;

Font, J ;

Sebastiani, GD ;

Gil, A ;

Lavilla, P ;

Mejía, JC ;

Aydintug, AC ;

Chwalinska-Sadowska, H ;

de Ramón, E ;

Fernández-Nebro, A ;

Galeazzi, M ;

Valen, M ;

Mathieu, A ;

Houssiau, FD ;

Caro, N ;

Alba, P ;

Ramos-Casals, M ;

Ingelmo, M ;

Hughes, GRV .

MEDICINE, 2003, 82 (05) :299-308

[9] Morbidity and mortality in systemic lupus erythematosus during a 5-year period -: A multicenter prospective study of 1,000 patients [J].

Cervera, R ;

Khamashta, MA ;

Font, J ;

Sebastiani, GD ;

Gil, A ;

Lavilla, P ;

Aydintug, AO ;

Jedryka-Góral, A ;

de Ramón, E ;

Fernández-Nebro, A ;

Galeazzi, M ;

Haga, HJ ;

Mathieu, A ;

Houssiau, F ;

Ruiz-Irastorza, G ;

Ingelmo, M ;

Hughes, GRV .

MEDICINE, 1999, 78 (03) :167-175

[10] A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome [J].

Crowther, MA ;

Ginsberg, JS ;

Julian, J ;

Denburg, J ;

Hirsh, J ;

Douketis, J ;

Laskin, C ;

Fortin, P ;

Anderson, D ;

Kearon, C ;

Clarke, A ;

Geerts, W ;

Forgie, M ;

Green, D ;

Costantini, L ;

Yacura, W ;

Wilson, S ;

Gent, M ;

Kovacs, MJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (12) :1133-1138

← 1 2 3 4 5 →